Retrogen

Retrogen is an established, privately-held service provider in the genomics and diagnostics sector, leveraging both foundational Sanger sequencing and modern NGS platforms like Ion Torrent PGM and Oxford Nanopore. Its business model is dual-focused, serving research clients with genomic services while also operating a CLIA/CAP-accredited clinical lab for diagnostic testing, including COVID-19 and genetic disease panels. The company has built a stable revenue-generating operation by catering to diverse customer segments from academia to healthcare, though it operates in a highly competitive commoditized service market. Its strategic positioning combines technical reliability with a expansion into higher-value clinical diagnostic applications.

Multi-platform sequencing service provider utilizing Sanger, Ion Torrent PGM (with AmpliSeq panels), and Oxford Nanopore technologies for genomic analysis and clinical diagnostics.

Retrogen competes with large commercial service providers (e.g., Azenta, Eurofins), university core facilities, and other regional CLIA labs. Its differentiation is based on a long track record, multi-platform flexibility, and a hybrid research/clinical model. However, it lacks the scale, brand recognition, and comprehensive global reach of the largest players in the space.